In summary, shorter course ascending dose vivax malaria radical cure regimens in G6PD-deficient subjects offer the prospect of an effective treatment which does not incur prohibitive haemolytic toxicity and in some areas could obviate the need to test for G6PD deficiency. This evidence concerns the gene G6PD and G6PD deficiency.